日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bioactive compounds from ShenFuShanYuRou decoction enhance Treg cell function against hemorrhagic shock injury via Stat1- and Gbp5-dependent FOXP3 induction

参莪山郁肉汤中的生物活性成分通过 Stat1 和 Gbp5 依赖的 FOXP3 诱导增强 Treg 细胞对出血性休克损伤的功能。

Huang, Qingxia; Wu, Mingxia; Ding, Lu; Guo, Chen; Wang, Yisa; Man, Zhuo; Su, Hang; Li, Jing; Chen, Jinjin; Yao, Yao; Wang, Zeyu; Zhao, Daqing; Zhao, Linhua; Tong, Xiaolin; Li, Xiangyan

Circ_0001047 inhibits prostate cancer progression and enhances abiraterone sensitivity via miR-122-5p/FKBP5/PHLPP1/AKT axis in vitro

Circ_0001047 体外通过 miR-122-5p/FKBP5/PHLPP1/AKT 轴抑制前列腺癌进展并增强阿比特龙敏感性

Zhenjie Chen #, Shi Fu #, Yiqian Shan #, Zexi He, Jun Gu, Haichao Wu, Jiawei Lin, Yinglong Huang, Haifeng Wang, Yangbai Lu, Mingxia Ding

[Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy]

[一名患有系统性红斑狼疮的女性患者在停止双靶点嵌合抗原受体T细胞疗法后安全妊娠和分娩]

Wang, Mingxia; Ding, Ling; Wang, Min; Zou, Chanjuan; Yan, Siyu; Liang, Yingwen; Wang, Weijia; He, Shanzhi

MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells

MicroRNA-98 通过靶向膀胱癌细胞中的 LASS2 促进耐药性并调节线粒体动力学

Ting Luan, Shi Fu, Lijuan Huang, Yigang Zuo, Mingxia Ding, Ning Li, Jian Chen, Haifeng Wang, Jiansong Wang

A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro

新型单克隆抗体KMP1通过阻断体内和体外的CD44具有潜在的抗膀胱癌肿瘤活性

Yujin Chen, Haifeng Wang, Yigang Zuo, Ning Li, Mingxia Ding, Chong Li

LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity

LASS2 通过调节 ATPase 活性抑制膀胱癌的生长和侵袭

Haifeng Wang, Yigang Zuo, Mingxia Ding, Changxing Ke, Ruping Yan, Hui Zhan, Jingyu Liu, Wei Wang, Ning Li, Jiansong Wang

miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer

miR-9 通过靶向 LASS2 促进膀胱癌细胞增殖并抑制细胞凋亡

Haifeng Wang, Wei Zhang, Yigang Zuo, Mingxia Ding, Changxing Ke, Ruping Yan, Hui Zhan, Jingyu Liu, Jiansong Wang